Get full access to one story every week, and to summaries of all other stories. Just create a free account

For a while now, India’s cherished malted drink brands—Horlicks and Complan—have been caught in a race. Not just for market share, but to find new owners.

That race ended last month, when Ahmedabad-based pharma group Zydus scooped up Complan from consumer goods company Kraft Heinz. A mirror story is expected to play out when pharmaceutical company GlaxoSmithKline India sheds its Horlicks brand, which has been on the auction block since March. Horlicks has a host of non-pharma suitors—Pepsi, Coke, Unilever and Nestle. While its parent, GSK Plc, has signalled its intent to double down on the consumer health business by buying out Novartis’ share in their consumer health joint venture for $13 billion, it’s cropping its consumer health portfolio in India.

Serious swapping, selling, and shedding of assets have been the hallmarks of Big Pharma in the past year. Germany’s Merck sold its consumer health business to Proctor & Gamble. In India, this amounted to selling one of the largest vitamins and supplements businesses for Rs  1,290 crore ($177.9 million). Others, too, have pared their consumer business—where the profits are inherently not as high as pharmaceuticals—having been squeezed due to fickle retail’s reversals and creative rebirth.

Big Pharma, in general, is facing a challenging environment for gaining reimbursement for high-priced medicines in developed markets. Lawmakers, patients and doctors are paying closer attention to price increases, while insurers are pushing back against expensive medicines.

Most companies are using the proceeds of these sales to prop up their pipelines and go back to basics—innovate and launch new drugs. The ricochets in India mean multinationals are reassessing their bets. Quite a few have been quietly downsizing, laying off workers by the hundreds; something Big Pharma has rarely done in over a decade in India. Especially since 2005, when the new World Trade Organisation-compliant product patent regime kicked in. Many like Bristol-Myers Squibb, Boehringer Ingelheim, and MSD set up their subsidiaries just around that time. The lure was the growing domestic market and the promise of India as a cost-effective R&D post with new IP protection.

The champagne has now gone flat. The Christmas tree, as it were, is off to be mulched. Industry insiders say even long-termists like Pfizer, GSK, and AstraZeneca—who have seen a decline in revenues (or even de-growth)—are letting people go. This downsizing at private companies like Bristol-Myers Squibb and Roche Products is reflected in the 30-40% decline in their employee benefits expenses. India corporate filings show gallows sensibilities—margins down to low single digits, operational revenues growth are anaemic at best.

MNCs have never downsized in the past. This time it's unusual. Profits are squeezed and sustaining a large field force is no longer possible

Inderjeet Sood, Pharma consultant, Mumbai

“Each Big Pharma company is looking for its own equilibrium and is, therefore, realigning its priorities.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 6 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.